Janssen Redefines Clinical Trial Design by Leveraging Wearable Technology

 Janssen Redefines Clinical Trial Design by Leveraging Wearable Technology

Janssen Redefines Clinical Trial Design by Leveraging Wearable Technology

Shots:

  • Janssen is reimagining digital clinical trial design with the launch of a CHIEF-HF study. The study will evaluate Invokana (canagliflozin) vs PBO in patients aged ≥18yrs. with either preserved or reduced ejection fraction HF, with or without T2D
  • The CHIEF HF study will utilize personal smartphones and wearable devices to track patient outcomes via app-based clinical questionnaires and physical activity data logged by an app on the smartphone and actigraphy data from a wearable activity device, with no in-person clinical visits required
  • CHIEF-HF is the first-ever completely decentralized, mobile, indication-seeking study, design with the potential to bring faster & cost-effective therapies to the patients. The study plans to enroll ~1,900 participants in the US

Click here to­ read full press release/ article | Ref: Janssen | Image: Studioscalzi

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post